Depression drug approval fuels US recruitment

Danish drugmaker Lundbeck is cutting 180-200 jobs in Europe as part of its ongoing restructuring programme. However, the company is currently in the process of expanding its staff in the US.

That expansion will serve to deal with increased US business, following the Food and Drug Administration’s (FDA) approval of Lundbeck and Takeda’s new drug for depression, Brintellix (vortioxetine). The drug has a complex pharmacological profile, interacting with several different 5-hydroxytrypamine receptors. Lundbeck admits that the clinical significance of this pharmacological activity is not well understood, but the drug has performed well enough in clinical trials to convince the regulators.